Press Releases

Feb 7, 2023

Fractyl Health gibt die kommerzielle Verfügbarkeit von Revita in Deutschland und das® erste erfolgreiche Verfahren beim 25. Internationalen Endoskopie-Symposium in Düsseldorf bekannt

Der erste Patient mit Typ-2-Diabetes (T2D) erhielt Revita®in Deutschland, wo das Revita DMR System™über eine CE-Kennzeichnung und Kostendeckung im Rahmen des NUB-Erstattungsprozesses verfügt ImRahmen des 25. ...

Read More

Feb 7, 2023

Fractyl Health Announces Commercial Availability of Revita® in Germany and Successful First Procedure at 25th Düsseldorf International Endoscopy Symposium

First patient in Germany with Type 2 Diabetes (T2D) received Revita® in Germany, where the Revita DMRSystem™ has a CE Mark and insurance coverage through the NUB reimbursement process Live demonstration of a Re...

Read More

Jan 31, 2023

Fractyl Health Provides Clinical Update on 24-Week Data from Open Label REVITA-T2Di Cohort

Revita-T2Di is an open-label cohort evaluating Revita® in patients with insulin-treated Type 2 Diabetes Revita in the T2Di cohort has been observed to be well tolerated, with clinically meaningful improvements in...

Read More

Dec 5, 2022

Fractyl Health Announced Positive Proof-of-Concept Data of Pancreatic GLP-1 Gene Therapy in a Type 2 Diabetes Animal Model at the 20th World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

POC efficacy data in rodents shows that a novel adeno-associated virus (AAV) pancreatic gene therapy platform can confer dose-dependent effects on improving insulin production and reducing blood sugar Dose-depend...

Read More

Nov 2, 2022

Fractyl Health Initiates Landmark Scientific Partnership to Study Root Cause Mechanisms Underlying Type 2 Diabetes

Newly formed Erase T2D task force comprises leading scientists and pioneering scientific research to elucidate the role of the duodenum in type 2 diabetes and metabolic control Fractyl Health-supported research pr...

Read More

May 22, 2022

Fractyl Health Presents New Mechanistic Data on Revita® DMR in Type 2 Diabetes

Patients treated with Revita experienced a 0.8%-point reduction in HbA1c along with a 33% improvement in markers of insulin sensitivity three months after undergoing the procedure Markers of insulin production cap...

Read More

May 17, 2022

Fractyl Health to Present New Data on Revita® DMR in Type 2 Diabetes at Digestive Disease Week 2022

Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), will share new data in an oral presentation during the 2022 Digestive Diseas...

Read More

Apr 4, 2022

Fractyl Health Announces FDA IDE Approval to Begin Revitalize-2 Pivotal Study Designed for Patients with Type 2 Diabetes (T2D) Who Are Not Yet on Insulin

Revitalize-2 is the second pivotal study for the Revita DMR® system (Revita®) in Fractyl Health’s Revitalize T2D clinical development program   Revitalize T2D is designed to evaluate the potential of Revita i...

Read More

Feb 8, 2022

Fractyl Health Receives Reimbursement Authorization in Germany for Revita DMR® System

The Revita DMR System (Revita) gains reimbursement authorization from the German Institute for Hospital Remuneration (InEK) with a NUB Status 1 designation NUB Status 1 entitles participating hospitals in German...

Read More

Feb 1, 2022

Fractyl Health Publishes Two-Year Durability Data After a Single Revita DMR® Therapeutic Procedure in Patients with Type 2 Diabetes

REVITA-1 was an open-label cohort study evaluating Revita® in patients with type 2 diabetes on oral anti-diabetic agents but not yet on insulin This is the first publication showing two-year durability of impro...

Read More

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Fractyl Health disavows any obligation to update the information contained in such press releases after the date of their issuance.

Media Contact: Beth Brett, Corporate Communications , +1 (720) 656-6544

In the News

You are now leaving the website

You are leaving Fractyl’s main website to go to Fractyl’s U.K. site.

By selecting Continue you will be directed to Fractyl’s U.K. site. If you would like to remain on Fractyl’s main site, select the Cancel button.